(Q37449784)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19375622%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

review article

1 reference

title

Critical appraisal of prostate-specific antigen in prostate cancer screening: 20 years later (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19375622%20AND%20SRC:MED&resulttype=core&format=json

prostate cancer screening

26 January 2020

main subject

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19375622%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

1

Kenneth J Pienta

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 May 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19375622%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19375622%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

volume

73

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19375622%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

page(s)

S11-20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19375622%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

issue

5 Suppl

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19375622%20AND%20SRC:MED&resulttype=core&format=json

What to do with an abnormal PSA test.

26 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

AN " ACID " PHOSPHATASE OCCURRING IN THE SERUM OF PATIENTS WITH METASTASIZING CARCINOMA OF THE PROSTATE GLAND

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

New circulating biomarkers for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

"BPSA," a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

Transrectal ultrasound in the diagnosis and staging of prostatic carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

Characteristics of prostate cancers detected in a multimodality early detection program. The Investigators of the American Cancer Society-National Prostate Cancer Detection Project

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

Prostate cancer screening: current trends and future implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

The discovery of prostate specific antigen as a biomarker for the early detection of adenocarcinoma of the prostate.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

Reasons why patients reject digital rectal examination when screening for prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

An abnormal digital rectal examination is an independent predictor of Gleason > or =7 prostate cancer in men undergoing initial prostate biopsy: a prospective study of 790 men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

Predicting the outcome of prostate biopsy: comparison of a novel logistic regression-based model, the prostate cancer risk calculator, and prostate-specific antigen level alone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

Screening for prostatic carcinoma with prostate specific antigen: results of the second year.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

Utilization of polyclonal serum prostate specific antigen levels in screening for prostate cancer: a comparison with corresponding monoclonal values

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

Prostate-specific antigen levels in the United States: implications of various definitions for abnormal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

Guideline for the management of clinically localized prostate cancer: 2007 update.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

Age-specific reference ranges for serum prostate-specific antigen in black men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

Investigating Black-White differences in prostate cancer prognosis: A systematic review and meta-analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

Effect of Finasteride on the Sensitivity of PSA for Detecting Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

EAU guidelines on prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

The effects of prostatic manipulation on prostate-specific antigen levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

The effect of urethral catheterisation on serum prostate- specific antigen levels in male patients with acute urinary retention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

Associations of lifestyle and physiologic factors with prostate-specific antigen concentrations: evidence from the National Health and Nutrition Examination Survey (2001-2004).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

Overdiagnosis and overtreatment of early detected prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

7 January 2021

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

Prostate-specific antigen in the early detection of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

Recent trends in prostate cancer mortality show a continuous decrease in several countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

The PSA testing dilemma: GPs' reports of consultations with asymptomatic men: a qualitative study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

Screening for prostate cancer (PC)--an update on recent findings of the European Randomized Study of Screening for Prostate Cancer (ERSPC).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

Overdiagnosis in early detection programs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

Overdiagnosis Due to Prostate-Specific Antigen Screening: Lessons From U.S. Prostate Cancer Incidence Trends

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

The evolving biology and treatment of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

Under diagnosis and over diagnosis of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

Under diagnosis and over diagnosis of prostate cancer in a screening population with serum PSA 2 to 10 ng/ml

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

Relationship of first-year costs of treating localized prostate cancer to initial choice of therapy and stage at diagnosis: results from the CAPSURE database

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part IV: Estimating the risks and benefits of an early detection program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

Early detection of prostate cancer. Part II: Estimating the risks, benefits, and costs. American College of Physicians

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

PSA-based screening for prostate cancer: how does it compare with other cancer screening tests?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

Screening for prostate cancer: an update of the evidence for the U.S. Preventive Services Task Force

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

Mortality results from a randomized prostate-cancer screening trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

Screening and prostate-cancer mortality in a randomized European study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

Prostatic specific antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.02.016

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.UROLOGY.2009.02.016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19375622%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

1 reference